• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study.

作者信息

Georgakopoulos J R, Ighani A, Zhou L L, Yeung J

机构信息

Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.

Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

出版信息

J Eur Acad Dermatol Venereol. 2018 Jan;32(1):e32-e34. doi: 10.1111/jdv.14468. Epub 2017 Aug 2.

DOI:10.1111/jdv.14468
PMID:28695989
Abstract
摘要

相似文献

1
Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study.司库奇尤单抗治疗加拿大两家实际临床皮肤科诊所中重度斑块状银屑病的疗效与安全性：一项多中心回顾性研究
J Eur Acad Dermatol Venereol. 2018 Jan;32(1):e32-e34. doi: 10.1111/jdv.14468. Epub 2017 Aug 2.
2
Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.69 例中重度斑块型银屑病患者使用司库奇尤单抗的有效性和安全性：一项回顾性多中心研究。
Dermatol Ther. 2017 Nov;30(6). doi: 10.1111/dth.12550. Epub 2017 Sep 14.
3
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.司库奇尤单抗在清除中重度斑块型银屑病患者皮肤方面优于乌司奴单抗：来自 CLEAR 研究的结果。
J Am Acad Dermatol. 2017 Jan;76(1):60-69.e9. doi: 10.1016/j.jaad.2016.08.008. Epub 2016 Sep 20.
4
Secukinumab: a review in moderate to severe plaque psoriasis.司库奇尤单抗：治疗中重度斑块状银屑病的研究进展。
Am J Clin Dermatol. 2015 Aug;16(4):323-330. doi: 10.1007/s40257-015-0143-7.
5
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).司库奇尤单抗治疗中重度银屑病患者 5 年，疗效持久且安全性良好（SCULPTURE 扩展研究）。
J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507-1514. doi: 10.1111/jdv.14878. Epub 2018 Mar 22.
6
Real-world effectiveness and safety of risankizumab in adult patients with plaque psoriasis: A 1-year international multicenter retrospective cohort study.司库奇尤单抗在成年斑块状银屑病患者中的真实世界有效性和安全性：一项为期1年的国际多中心回顾性队列研究。
J Am Acad Dermatol. 2024 Sep;91(3):513-515. doi: 10.1016/j.jaad.2024.03.048. Epub 2024 Apr 25.
7
Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study.司库奇尤单抗治疗中重度掌跖脓疱型银屑病：2PRECISE 研究结果。
J Am Acad Dermatol. 2019 May;80(5):1344-1352. doi: 10.1016/j.jaad.2019.01.066. Epub 2019 Feb 1.
8
Secukinumab (AIN-457) for the treatment of Psoriasis.司库奇尤单抗（AIN-457）用于治疗银屑病。
Expert Rev Clin Pharmacol. 2016;9(2):187-202. doi: 10.1586/17512433.2016.1129894.
9
Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.司库奇尤单抗治疗掌跖银屑病的疗效显著：来自 GESTURE 的一项随机对照试验结果。
J Am Acad Dermatol. 2017 Jan;76(1):70-80. doi: 10.1016/j.jaad.2016.07.058. Epub 2016 Oct 1.
10
Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study.司库奇尤单抗治疗常规临床中的中重度斑块型银屑病：来自 PROSPECT 研究的既往和同时使用银屑病治疗药物的真实世界数据。
J Eur Acad Dermatol Venereol. 2018 Mar;32(3):411-419. doi: 10.1111/jdv.14604. Epub 2017 Nov 22.

引用本文的文献

1
Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi real-world setting.沙特真实世界环境中司库奇尤单抗治疗银屑病和银屑病关节炎患者的疗效。
Adv Rheumatol. 2024 Apr 29;64(1):34. doi: 10.1186/s42358-024-00371-1.
2
Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study.中国中重度斑块型银屑病成年患者司库奇尤单抗治疗结局：一项真实世界、多中心回顾性研究。
Clin Transl Sci. 2023 Oct;16(10):1803-1814. doi: 10.1111/cts.13583. Epub 2023 Aug 29.
3
Real-World Satisfaction with Secukinumab in Clearing the Skin of Patients with Plaque Psoriasis through 24 Months of Follow-Up: Results from US Dermatology Electronic Medical Records.
通过24个月随访观察司库奇尤单抗清除斑块状银屑病患者皮肤的真实世界满意度：来自美国皮肤科电子病历的结果
Dermatol Ther (Heidelb). 2021 Oct;11(5):1733-1749. doi: 10.1007/s13555-021-00599-5. Epub 2021 Aug 28.
4
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study.司库奇尤单抗治疗中重度银屑病患者的疗效持久且稳定：来自 SUPREME 研究的结果。
Acta Derm Venereol. 2021 Oct 21;101(10):adv00576. doi: 10.2340/00015555-3816.
5
Practical experience of secukinumab in the treatment of psoriasis: experience from a single centre.司库奇尤单抗治疗银屑病的实践经验：单中心经验。
Ir J Med Sci. 2021 May;190(2):639-641. doi: 10.1007/s11845-020-02336-x. Epub 2020 Aug 11.
6
Interleukin-33 alleviates psoriatic inflammation by suppressing the T helper type 17 immune response.白细胞介素-33 通过抑制辅助性 T 细胞 17 免疫应答缓解银屑病炎症。
Immunology. 2020 Aug;160(4):382-392. doi: 10.1111/imm.13203. Epub 2020 May 25.
7
Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis.司库奇尤单抗：用于治疗银屑病的抗白细胞介素-17A生物制剂。
Case Rep Dermatol. 2019 Sep 20;11(Suppl 1):1-3. doi: 10.1159/000501991. eCollection 2019 Sep-Dec.
8
A Pilot Study to Assess the Feasibility of a Web-Based Survey to Examine Patient-Reported Symptoms and Satisfaction in Patients with Ankylosing Spondylitis Receiving Secukinumab.一项评估基于网络的调查在接受司库奇尤单抗治疗的强直性脊柱炎患者中检查患者报告症状和满意度的可行性的试点研究。
Drugs Real World Outcomes. 2019 Jun;6(2):83-91. doi: 10.1007/s40801-019-0154-4.
9
Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement.司库奇尤单抗在真实世界中治疗银屑病的有效性和安全性：按既往生物制剂治疗失败或报销情况分层的亚组分析
Ther Adv Chronic Dis. 2019 Apr 17;10:2040622319843756. doi: 10.1177/2040622319843756. eCollection 2019.